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In this study we have applied exome sequencing of the X-chromosome in order 
to identify a mutation in a Finnish family with X–Linked Intellectual Disability 
(XLID). We identified a novel mutation in the Cullin 4B gene (CUL4B) that has 
previously shown to cause Cabezas syndrome. The mutation was identified us-
ing Agilent array that covers 93% of the coding region of chromosome X. The 
mutation is located in exon 20 resulting in premature stop codon in exon 21 
where aspartic acid is changed to a premature stop codon D806X. Here we 
present a detailed clinical phenotype of the three affected brothers.  CUL4B is a 
ubiquitin E3 ligase subunit implicated in the regulation of several biological 
processes, and CUL4B is the first XLID gene that encodes an E3 ubiquitin li-
gase. Our findings elucidate the functional significance of CUL4B in human 
cognition and in other aspects of human development. 
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1. INTRODUCTION 
 
Intellectual disability (ID) can be defined as a significantly reduced ability 
to interpret new or complex information, and to learn new skills with a reduced ability 
to cope independently. It is characterized by significant limitations both in intellectual 
functioning as well as in adaptive behaviour with onset before the age of 18 years. 
[Luckasson et al. 2002]. The prevalence of intellectual disability in developed countries 
is between 1% and 3% and is responsible for 5 to 10 % of health care expenditure in 
some developed countries [Ropers. 2008]. 
X-linked Intellectual Disability (XLID) is a clinically complex and heterogeneous dis-
order, [Gecz et al. 2009] and mutations in more than 90 genes X chromosomal genes  
have been found to be associated with this disease [Tarpey et al. 2009; Ropers. 2010]. 
X-linked gene defects are thought to be the important causes of intellectual disability 
and they account for roughly 10 -15 % of the intellectual disability in males [Hamel et 
al. 2008]. Intellectual disability can be an outcome of genetic as well as environmental 
causes that act on the development and functioning of the CNS prenatally, perinatally or 
postnatally [Chiurazzi et al. 2008]. Genetic causes can be due to large deletions, large 
duplications or aneuploidies that affect multiple genes. It can also be due to mutations 
of individual genes leading to autosomal dominant, autosomal recessive or X linked 
genetic disease. [Inlow et al. 2004]. 
Among intellectually disabled patients, an excess of males has been observed and is 
explained by the fact that the presence of many genes responsible for ID are on the X 
chromosome than on the autosomes [Lehrke R. 1972]. 
X-linked intellectual disability is divided into syndromic and non syndromic forms. In 
syndromic forms ID is expressed with a specific pattern of physical, neurological, 
and/or metabolic abnormalities. In non-syndromic X- linked intellectual disability male 
patients have no consistent phenotypic manifestations other than intellectual disability. 
[Renieri et al. 2005]. 
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2. THEORETICAL BACKGROUND 
 
2.1 Definition of Intellectual Disability  
Intellectual disability is a disability until recently referred to as mental retardation is   
characterized  by the significant limitations both in intellectual functioning and adaptive 
behaviour as expressed in conceptual, social  and practical adaptive skills. This disabil-
ity originates before the age of 18. [Schalock et al. 2007]. 
According to the tenth revision of the WHO (World Health Organization), Intellectual 
Disability is a disorder defined by the presence of incomplete or arrested mental devel-
opment, principally characterized by the deterioration of concrete functions at each 
stage of development that contributes to the overall level of intelligence such as cogni-
tive, language, motor and socialization functions where adaptation to the environment is 
always affected. 
According to the American Association on Intellectual Disabilities (AAIDD), there are 
five assumptions that are essential for the application of the definition of intellectual 
disability: 
1. Limitations in present functioning must be considered within the context of commu-
nity environments typical of the individual‘s age peers and culture. 
2. Valid assessment considers cultural and linguistic diversity as well as differences in 
communication, sensory, motor, and behavioral factors. 
3. Within an individual, limitations often coexist. 
4. An important purpose of describing limitations to develop a profile of needed sup-
ports. 
5. With appropriate personalized supports over a sustained period, the life functioning 
of the person with intellectual disability generally will improve. 
[AAIDD, http://www.aaidd.org/] 
In contrast, the WPA Section on Psychiatry of Intellectual Disability considers IDD to 
be a health condition: a syndromic grouping or meta-syndrome analogous to the con-
struct of dementia, which is characterized by a deficit in cognitive functioning prior to 
the acquisition of skills through learning. The intensity of the deficit is such that it inter-
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feres in a significant way with individual normal functioning as expressed in limitations 
in activities and restriction in participation (disabilities).[Carulla et al.  2008.] 
 
Table 1: LIMITATIONS ASSOCIATED WITH INTELLECTUAL DISABILITY 
1. Communication  
2. Personal Care 
3. Home Life 
4. Social Skills 
5. Utilization of the Community 
6. Health and Safety 
7. Functional academic skills 
8. Leisure Time 
9. Work 
* Based on American Association on Intellectual and Developmental Disabilities (AAIDD). 
 
Clinically ID is described by three basic criteria:  
a) an intelligence quotient (IQ) below 70  
b) limitation in two or more adaptive behaviors such as communication, self care, social 
skills, community use, self direction, health and safety  
c) evidence that the mental manifestations began before the age of 18. 
Four degrees of severity of intellectual impairment can be categorised: mild, moderate, 
severe, and profound. (Refer Table 2) 
Mild: About 50 % of persons fall into this category. People with this level of ID need 
support on as needed basis, episodic or short term. IQ ranges from 50-55 till 70. 
Moderate: This group constitutes about 10 % of the entire population of people with 
ID. The IQ level usually varies from 35-49 till 50-55. They need support consistent with 
time but the amount of time is limited. 
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Severe: This group constitutes of 3% - 4% of individuals with ID. People in this group 
need regular, consistent and lifetime support. Regular support is needed in at least one 
such aspect such as school, work or home. The IQ level ranges from 20-25 till 35- 40. 
Profound: This group approximately constitutes 1%- 2% of people with intellectual 
disability. They possess little or no ability to care for their own basic needs and require 
constant help and supervision. IQ level is under 20-25.  
 
Table 2: Classification of Intellectual Disability  
Security Level 
(Percentage of Individu-
als with ID) 
Intelligent Quotient 
Range 
Support needed in daily 
living activities 
Mild (50%) From 50-55 till 70 Intermittent 
Moderate (10%) From 35-49 till 50-55 Limited 
Severe (4%) From 20-25 till 35-40 Extensive  
Profound (1%) Less than 20-25 Pervasive 
Based on American Psychiatric Association, DSM-IV TR, 2000; American Association of Intel-
lectual and Developmental Disabilities, 2002. 
2.2 Prevalence of Intellectual Disability  
The prevalence of ID is estimated to affect approximately 2 % to 3 % of the population. 
X linked gene defects are considered to be responsible for approximately 10 % of the ID 
found in males (Ropers et al. 2005). Their prevalence is around 1% in high income 
countries and 2 % in low and middle income countries [Maulik et al. 2011; Durkin. 
2002]. 
 
2.3  X-Linked  Intellectual Disability 
X-linked mental retardation is the proportion of mental retardation showing the distinc-
tive pattern of inheritance associated with the X chromosome. The XLID phenotype in a 
family can be detected when the transmission follows the general characteristics of X-
linked recessive phenotypes: 
 only males are affected 
 all daughters of affected males will be carriers 
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 carrier females may have mild expression of the disease 
 sons of carrier females have a 50% risk of being affected 
 daughters of carrier females have an 50% risk of being carriers 
 male to male transmission does not occur 
 unaffected males cannot transmit the phenotype 
 
 
 
Figure 1. X chromosomal pedigree adapated from Human Molecular Genetics by Stratchan and Andrew P 
Read, Wiley Liss (1999). 
 
2.4 X Chromosome 
X chromosome has many attributes that are exclusive in the human genome. The size of 
the X chromosome is roughly 155MB and contains a total of 1860 genes (Figure 2). The 
X chromosome holds a special place in the field of Medical Genetics. Although the X 
chromosome contains only 4 % of the genes, it is accountable for almost 10 % of the 
diseases with the Mendelian Inheritance.  X chromosome inactivation in mammals at-
tains dosage compensation between males and females for X linked gene products. Fe-
males inherit an X chromosome from each parent but males inherit only a single mater-
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nal X chromosome. [Ross et al. 2005]. Intellectual disability is one among the common  
problems in  clinical genetics and it affects more males than females. Many genes on the 
human X chromosome get away from X-inactivation, or at least partly. For most of 
these, there is no functionally comparable homologue on the Y chromosome, which 
itself explains the gender –specific distinction  accountable  for  the susceptibility to 
certain diseases. [Ropers. 2006]. 
 
Figure 2. The Composition of X chromosome. Adapted from 
http://vega.sanger.ac.uk/Homo_sapiens/Location/Chromosome?r=X 
 
2.5 Classification of XLID 
XLID is usually categorized into the ―syndromic‖ and ―non syndromic‖ forms. In the 
syndromic forms, Intellectual disability is present in association with specific pattern of 
physical, neurological and/or metabolic abnormalities. Until now out of 215 total condi-
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tions 98 genes related to syndromic ID have been identified 
(http://xlmr.interfree.it/home.htm). The term non specific XLID was coined by Kerr et 
al. in 1991 to illustrate the condition segregating in an X linked manner in which the 
male patients do not demonstrate any  specific phenotypic manifestations  other than the 
Intellectual Disability  [Kerr et al. 1991; Mulley et al. 1992]. Till date 66 genes related 
to non-specific XLID out of the total 215 genes have been identified. 
(http://xlmr.interfree.it/home.htm). ID can be an outcome of genetic as well as environ-
mental factors that are responsible for affecting the development and normal function-
ing of the nervous system prenatally, perinatally and postnatally. It can also be due to 
various environmental factors mainly malnutrition in pregnancy, pre- and postnatal in-
fections, exposure to neurotoxic compounds, premature birth and peri- and postnatal 
asphyxia or other trauma. The genetic causes of ID are mainly recognized in severe in-
tellectual disability and they involve chromosome aneusomies, chromosomal structural 
abnormalities, genomic disorders and monogenic disorders. Genetic factors account for 
roughly 65 % of moderate to severe ID [Chelly et al. 2006; Chiurazzi  et al. 2008; Patel  
et al. 2010]. 
2.6 Etiology of Intellectual Disability  
2.6.1 Environmental and sociocultural factors 
Epidemiological studies have repeatedly revealed that an evident link exists between the 
poverty and intellectual disability. It is clear that this notable link reflects two distinct 
processes. The first one indicating that a connection between poverty and exposure to a 
wide range of environmental and psychosocial factors exist and the second one reveals 
that families with members who suffer from intellectual disability have an increased risk 
of catastrophic expenses that considerably affect poverty levels. These factors are con-
sidered to be straight forward reasons of intellectual disability in developing countries. 
[Leonard  et al. 2005]. 
 
2.6.2 Chromosomal aberrations and ID 
Chromosomal abnormalities occur in 6% of all recognized congenital malformations, 
The most common ones listed in Table 3. 
Table 3: Chromosomal Abnormalities Associated with Intellectual Disability 
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SYNDROME PREVALENCE CHROMOSOMAL  
ABNORMALITY 
Down syndrome 1 in 1000 live births Approximately 94 % of the 
cases are caused by trisomy 
21, 3,5% by translocation, 
& 2,5 % by mosaicism. 
Turner’s syndrome 1 in 2000 to 1 in 5000  
females 
Complete or partial absence 
of one X chromosome (45, 
XO). 
Klinefelter’s syndrome  1 in 1000 males Maternal nondisjunction 
(47, XXY) 
Prader-Willi syndrome  1.2 to 1.3 per 10 000 Microdeletion on chromo-
some 15, paternal origin at 
the locus 15q11-13 
Angelman’s syndrome 1 in 20 000 to 1 in 30 000 Microdeletion on chromo-
some 15, maternal origin at 
the locus 15q11-13 
Cri-Du chat syndrome 1 in 50 000 deletion 5p 
Di-George syndrome 1 in 5000 microdeletion of  
chromosome  7q11 
Smith Magenis syndrome 1 in 25 000 microdeletion 17p11 
Rubinstein– Taybi  
syndrome 
1 in 12 500 live births  autosomal dominant,  
microdeletion  16p 13.3 
William’s syndrome  1 in 5 500 live births microdeletion of  
chromosome 7q11 
*Adapted from Ahuja et al. 2005. 
 
These account for 30% to 40% of severe intellectual disability and 10 % of mild intel-
lectual disability. [Raynham et al. 1996; Ahuja et al. 2005]. Chromosomal abnormalities 
include deletions, microdeletions, translocations, inversions and duplications. Sex 
chromosome anomalies occur in roughly 1 in 400 live births. These anomalies are 
commonly due to chromosomal nondisjunction, the risk of which increases with mater-
nal age. The most common include Turner‘s syndrome (45, XO), Klinefelter‘s syn-
 9 
drome (47, XXY) and the 47, XXX and 47, XYY karyotypes [Ahuja et al. 2005]. It is 
certainly true that individuals with chromosomal aneuploidy demonstrate some nonspe-
cific features in common such as poor growth, microcephaly, epicanthic folds and un-
usual palmar creases, in addition to features more specific to the chromosomes in-
volved. Down syndrome (trisomy 21) still remains the most important cause of intellec-
tual disability. Cytogenetically visible chromosomal aberrations are found almost in one 
out every seven individuals with severe cognitive impairment. [Leonard et al. 2002]. 
 
2.6.3 Copy number variants in Intellectual Disability  
The term "copy number variation" can referred to as  an  intermediate-scale genetic 
change, operationally defined as segments greater than 1,000 base pairs in length but 
typically less than 5 megabases, which is the cytogenetic level of resolution. CNVs in-
clude additional copies of sequences (duplications) and losses of genetic material (dele-
tions). [Eichler et al. 2008]. Unlike the SNPs the CNVs span larger regions which might 
affect one or more genes by decreasing or increasing the gene dosage, revealing a reces-
sive allele, causing aberrant expression or even might lead to alternative spliced or fu-
sion genes. Rare CNVs have been found to cause neurological disorders such as mental 
retardation, schizophrenia and autism [Redon et al. 2006; Marshall et al. 2008]. Studies 
to identify copy number variants (CNVs) on the X-chromosome have revealed novel 
genes important in the causation of X-linked Intellectual disability (XLID). Froyen and 
colleagues screened a cohort of 108 subjects with ID by X chromosome array CGH and 
identified CNVs in 14 subjects (13%). The most common XLID associated chromo-
somal  aberrations  reported are the duplications of Xq28 comprising the MECP2 gene, 
which have been found in more than 100 cognitively impaired individuals with charac-
teristic facial features, hypotonia, seizures, speech delay and recurrent infections [Van 
Esch  et al. 2005; Friez  et al. 2006; Madrigal  et al. 2007]. Approximately 10-15% of 
cases in intellectual disability in males have been reported due to copy number varia-
tions on the X chromosome [Fab et al. 2007; Koolen  et al. 2009]. Until now, very little 
has been known about the parental origin and the effect of increased parental age on the 
genesis of genomic copy number variation (CNV), including those which underlie a 
significant percentage of patients with cognitive disorder. Studies on a specific class of 
de novo CNVs—namely, those associated with recurrent microdeletion and microdupli-
cation syndromes—have implied  out that there is no significant bias in the parent of 
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origin. The majority of rare de novo CNVs associated with intellectual disability (ID), 
however, has non-recurrent breakpoints and does not generally involve known syn-
dromes [Koolen et al. 2009]. Numerous of CNVs have been found to be associated with 
specific phenotypes, and in patients with ID, recurrent interstitial microdeletions and 
duplications involving at least 19 genomic intervals have been identified [Vissers et al. 
2009]. For most of the CNVs associated in intellectual disability, reliable frequency 
estimates have not been determined to the extreme heterogeneity of ID and relatively 
limited size of the cohort analyzed so far. In one of the largest study reported so far, 
Mefford et al. (2008) reported on the frequency of recurrent CNVs at 69 out 130  puta-
tive genomic hot spots for NAHR in 1010 children with unexplained ID and also in 
2493 previously screened healthy adults. Pathogenic and possibly pathogenic CNVs 
were identified in 5.4% of the ID cohort [Itsara et al. 2009]. These studies reveal that 
CNVs are the basic cause of many specific forms of ID and various other disorders. In 
addition, numerous CNVs (at 1q21.1, 15q11.2, 15q13.3, 16p11.2, 16p13.11 and 
22q11.2) have been found to the major predisposing factors for wide spectrum of neu-
ropsychiatric disorders, including intellectual disability, autism and epilepsy [Mefford et 
al. 2008; Stefansson et al. 2008; Weiss et al.  2008]. 
 
2.6.4 Single base pair mutation  
A single base substitution can be defined where a single nucleotide is replaced by 
another nucleotide. These single base changes are also referred to as point mutations. 
They are the most frequent type of alterations in DNA. For example if a purine (a, t) is 
replaced by a purine and pyrimidine by a pyrimidine (c, g) then this kind of substitution 
is referred to as transversion. Single base substitutions are broadly categorized into four 
types mainly – missense mutations, nonsense mutations, silent mutations and splice site 
mutations. 
Missense mutation: In a missense mutation, the base alters the codon which results in a 
different amino acid being incorporated into the protein chain (Figure 3).  
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       Figure 3. Diagrammatic representation to illustrate a missense mutation. 
 
Lets take an example to illustrate missense mutations. In the above figure, the substitu-
tion of ―a‖ (highlighted in red) in the second codon to ―g‖ (highlighted in red) leads to 
an amino acid substitution of glutamine (Q) to arginine R. 
 
Nonsense mutation: In a nonsense mutation, the new base change in a codon cause one 
of the stop codons (taa, tag, tga). This will cause translation of mRNA to stop prema-
turely and a truncated protein is produced (Figure 4). 
 
 
 
 
 
 
 
    Figure 4. To illustrate nonsense mutations 
 
In the above figure the second codon ―c‖ is changing to ―t‖. In the normal nucleotide 
sequence the second codon ―cag‖ codes for glutamine (Q) while in the mutated second 
codon ―tag‖ codes for STOP leading to a premature termination of the protein. 
 
Silent mutation: Silent mutations are those that do not have any alteration in the final 
protein product and can only be identified by sequencing the gene. These do not have 
any deleterious effect as mutated codons will still be coding the same amino acid. 
                      L       Q    T 
NORMAL :  ctg   cag  act             nucleotide sequence 
                                
MUTATED: ctg  cgg  act    
                      L     R   T                protein sequence 
                     L     Q   T                                               protein sequence 
NORMAL :  ctg  cag  act                                        nucelotide sequence 
 
MUTATED: ctg   tag  act                  
                     L       
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In a recent study, exon screening of 86 known XLID genes yielded probably pathogenic 
mutations in no more than seven out of 21 families tested [Hao  et al. 2010]. Recent 
studies in a multigenerational German family revealed and confirmed the presence of 
novel GDI1 mutations with nonsyndromic intellectual disability.  Their study revealed a 
frameshift   mutation in GDI1 that co-segregated with the disease [Strobl-Wildemann et 
al. 2011]. Large scale next generation resequencing of the X chromosome genes have 
helped in identification of a missense mutation in the CLIC2 gene on Xq28 in a male 
with X linked Intellectual Disability [Takano  et al. 2011]. Mutations in the Jumonji AT 
–rich interactive domain 1C (JARID1C/SMCX/KDM5C) gene, located at Xp11.22 are 
emerging as frequent causes of X- linked intellectual disability [Fintelman et al. 2011]. 
 
Splice site mutation:  Changes in splicing can lead to the disease directly, modify the 
severity of the disease phenotype or be linked with disease susceptibility.  One large 
scale analysis of human genetic variation revealed  that 51 (1.3%) of the SNPs identi-
fied within and around the exons of 313 genes studied were found to be within the con-
sensus splice sites [Stephens et al. 2001]. Accurate pre –mRNA splicing  needs exon-
intron boundaries to be correctly recognized by the nuclear ribonucleoprotein complex 
known as the splicesome, for the introns to be correctly excised and also for the exons 
to be joined perfectly  to produce mature mRNA [Hastings  et al. 2001]. This process 
required the recognition of a variety of different motifs, including the fairly degenerate 
consensus sequences flanking the GT and AG dinucleotides at the 5‘ donor and 3‘ ac-
ceptor  splice sites  and also the branch site which almost some 15-35 bases upstream of 
the 3‘ splice site. In the Human Gene Mutation Database [Stenson et al. 2003], single 
base pair substitutions within the splice site constitute around 9.5% of all the mutations 
causing human inherited diseases. Splice site mutations may result in exon skipping, 
activation of the cryptic splice sites, creation of the pseudo-exon within an intron, or 
intron retention [Nakai et al. 1994]. Exon skipping is generally considered as the most 
common effect, and usually thought to be caused by the failure of the normal and mu-
tant splice sites to define an exon.  Most of the cryptic mutations initiate splice sites of 
the same type and are located within the few hundred nucleotides of the natural site 
[Hawkins 1988]. Also splice site mutations in very short or terminal introns have been 
found to result in intron retention [Dominski et al. 1991]. Usually mutations that are far 
away from the natural splice sites create cryptic sites that are activated in the presence 
of a nearby cryptic splice site of opposite polarity leading to production of a novel non-
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coding exon with the intron. Cryptic acceptor splice sites are more frequent in exons 
than in introns mainly due to depletion of AG dinucleotides upstream of the original 
acceptor sites [Christensen et al. 2005]. Intron retention is the least studied type of alter-
native and aberrant splicing. Compared to the other types of alternative splicing which 
involves the choice between different splice sites, intron retention represents complete 
absence of splicing. Retained introns have been found to be shorter than the constitu-
tively spliced out ones and also exhibited the tendency to occur in 5‘ and 3‘ untranslated  
regions [Sakabe  et al. 2007]. 
 
Figure 5. Classical splicing signal and modes of alternative splicing.  A) Conserved motifs at or near the 
intron ends. The nearly invariant GU and AG dinucleotides at the intron ends, the polypyrimidine tract  
preceding the 3‘ AG,  and  the A residue that serves as a branch point. B) Five common modes of alterna-
tive splicing. Adapted from Luca Cartegni et al.  2002.  
 
Sequence  alterations occurring in exons or introns may affect the correct processivity 
of the mRNA by disrupting the splice site, exonic splicing enhancers (ESE), intronic 
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splicing enhancers (ISE) or altering the secondary structure of the mRNA. In case of 
nonsense mutations suspected of affecting splicing, along with disruption of possible 
ESE and ESS, two other possible mechanisms are also involved. The first mechanism is 
referred to as nonsense mediated decay (NMD). In this case when a pretermination co-
don (PTC) is present the entire mRNA is degraded. Nonsense altered splicing is ac-
knowledged to be more controversial. In this case a translational like machinery scans 
the reading frame and surveys its integrity before splicing. It is still not clear how fre-
quently sequence variations involving splicing are involved in the onset of disease. In a 
survey conducted, where the mutations considered consisted only of those directly af-
fecting the standard consensus splice sites, 15% of mutations have been found to result 
in a human genetic disease through RNA splicing defects.[Krawczak  et al. 1992]. 
2.7 Identification of XLID genes 
Searching for genetic effects that are accountable for syndromic forms of XLID is not 
different from the various gene hunting procedures which we use for any monogenic 
condition. However finding molecular causes for NS-XLID has been really very chal-
lenging  due to its high level of genetic heterogeneity, which includes pooling of linkage 
information from unrelated families and all this greatlymakes it difficult to  search for 
the various mutations.  
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Figure 6. Ideogram of the X chromosome with the position of the syndromal XLID genes. Adapted from 
http://www.ggc.org/research/molecular-studies/xlid.html . 
 
Since 2000, the rate of identification of novel genes that cause intellectual disability has 
adavanced rapidly due to various technological advancements. Prior to this, most of the 
gene identification relied on linkage and positional cloning methods. In each large fami-
ly, the candidate interval for disease causing gene was found by identifying which parts 
of the X chromosome was shared by all the affected males and also not shared by unaf-
fected males in the family. Progress was later achieved by improved DNA sequencing 
methods and the coordination of two large international studies to identify the causative 
genes, EURO-MRX and IGOLD. Hence to overcome these hurdles and to study the 
molecular basis of NS-XLID, the European XLMR Consortium was founded in 1995 
and since then various members and the associated groups have made important contri-
butions to the identification of about 90 XLID genes identified so far 
(http://xlmr.interfree.it) (Figure 6 and 7). The search for XLID genes is still an ongoing 
process. There are various strategies for the identification of the various XLID genes.  
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Figure 7. Ideogram of the X chromosome with the position of the nonsyndromal XLID genes. Adapted 
from  http://www.ggc.org/research/molecular-studies/xlid.html . 
 
 
2.7.1 Positional Cloning & Linkage analysis  
Positional candidate gene studies are usually used to identify the disease genes for many 
human genetic diseases, and these studies involve genome wide linkage analysis to 
identify the approximate chromosomal location of a disease gene, fine structure genetic 
mapping to delineate and narrow the chromosomal interval in which the disease gene 
might be located, and also physical mapping and gene identification in the genetically 
defined interval to clone the disease gene.[Boehnke M.1994]. 
Positional cloning is based on the chromosomal localization of the gene. There is no 
previous knowledge of the biological function of the gene product. The overall strategy 
of positional cloning is to map the location of a human disease gene by linkage analysis 
and then to use the mapped location on the chromosome to clone the gene [Ballabio 
1993; Pierce 2003]. Positional cloning of genes responsible for XLID has been based on 
the investigation of X; autosome balanced translocations, deletion mapping or molecu-
lar screening of candidate genes [Castellvi-Bel and Milà 2001]. The disease genes iso-
lated by positional cloning usually fall into two main categories: (i) genes for relatively 
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common diseases with a large availability of pedigrees and samples for genetic mapping 
and that are the subject of intense research; (ii) genes representing ―easy‖ targets be-
cause of the presence of patients with readily visible cytogenetic abnormalities [Balla-
bio. 1993]. The identification of XLID genes is greatly facilitated by the presence of 
cytogenetic aberrations, like translocations, inversions and deletions. Translocations in 
mentally retarded patients provide an excellent opportunity to clone the X-chromosomal 
gene disrupted by the translocation. Males with microdeletions on the X chromosome 
are also informative and are often detected by the presence of a contiguous gene syn-
drome, in which X-linked disease phenotype is combined with intellectual disability 
[Chelly and Mandel 2001].  
For example Oligophrenin-1 (OPHN1) was identified after characterizing an X;12 ba-
lanced translocation in a female patient with mild intellectual disability [Billuart et al. 
1998]. Also TM4SF2 was identified by positional cloning after characterizing an X;2 
balanced translocation in a female patient with intellectual disability [Zemni et al. 
2000]. In addition ARHGEF6 was identified by a balanced X;21 translocation [Kutsche 
et al. 2000]. IL1RAPL gene was discovered with overlapping microdeletions in two XL-
ID families [Carrié et al. 1999]. 
 
2.7.2 High Throughput genomic DNA sequencing 
The most extensive approach would be to perform a high throughput genomic DNA 
resequencing of all the genes on the X chromosome (Figure 8).   
 
Figure 8. Diagram to illustrate systematic resequencing of X chromosome coding exons as an approach to 
identify novel X linked intellectual disability genes. (Figure adapted from Sanders, 2010) 
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A direct systematic sequencing has been a new approach whereby all coding exons of 
the X chromosome are fully sequenced in the male XLID or in a female obligate carrier. 
And from this screen a catalogue of X chromosome sequence variants are generated, 
some of which will be causative.  
Various variants are further analyzed to determine whether they are disease causing. 
Large-scale systematic resequencing has been anticipated as the future strategy for the 
discovery of rare, disease-causing sequence variants across the range of various human 
complex diseases. Tarpey et al (2009) have sequenced the coding exons of 718 X chro-
mosome genes in 208 families with X-linked Intellectual Disability, which has been the 
largest direct screen which is reported so far. The average coverage of the genes re-
ported here was 75%. 1,858 different coding sequence variants were detected, around 
1,769 from the X specific and 89 from the pseudoautosomal X chromosome regions. 
Also 1,814 single nucleotide changes were reported out of which 980 were causing mis-
sense amino acid substitutions, 22 were responsible for causing nonsense termination 
codons, 13 were abnormalities at highly conserved bases at splice acceptor and donor 
sites and 799 were causing silent changes. Three variants were missense double nucleo-
tides substitutions, and 41 variants detected small insertions and deletions of which 26 
were in frame and 15 were causing translational frameshifts. This dataset has helped in 
discovering nine genes implicated in XLID, namely AP1S2, BRWD3, UPF3B, CUL4B, 
ZDHHC9, SLC9A6, SYP, ZNF711 and CASK reported. Also this study emphasized the 
challenges which are faced in whole genome sequencing screens, specially the loss of 
function of 1 % or more of X chromosome genes. 
 
2.7.3 Array Technology 
Comparative genomic hybridization, CGH is a molecular cytogenetic method for the 
detection of chromosomal imbalances, which does not depend on the availability of 
chromosome spreads and is not limited to the analysis of growing cells [Solinas et al. 
1997; Pinkel et al. 1998]. In conventional CGH, two differentially labeled genomes, a 
test and control, are competitively hybridized to metaphase chromosomes. Regions of 
gain or loss of DNA sequences, such as deletions, duplications, or amplifications, are 
seen as changes in the ratio of the intensities of the two fluorochromes along the target 
chromosomes [Kallioniemi et al. 1992]. However, since the DNA in metaphase chro-
mosomes is condensed, the resolution is limited to 5-10 Mb. Thus, there is little reason 
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to apply CGH to chromosomes of metaphase cells in routine diagnostic settings [Lichter 
et al. 2000]. 
Recently, the drawbacks of conventional chromosomal CGH have been overcome by 
the introduction of array CGH. Here differentially labeled test and reference DNA are 
co-hybridized onto microarrays. Metaphase chromosomes are replaced with slides ar-
rayed with complementary DNA (cDNA) oligonucleotides or genomic BAC clones as 
the targets for analysis. Chromosomal microarrays allow the genome wide identification 
of submicroscopic chromosomal abnormalities at a very high resolution. The first array-
CGH experiments in patients with ID relied on the use of homemade bacterial artificial 
chromosome (PAC) arrays and had a diagnostic yield of about 10% [Vissers  et al. 
2003]. It does not require an expert clinician to suspect a specific diagnosis and it may 
cover the entire genome or targets known pathologic loci in a unique test. This new 
technique has been successful in revealing submicroscopic chromosome aberrations in 
patients with intellectual disability with normal results from prior cytogenetic analysis 
with detection rate up to 5- 20% [Liang  et al. 2008]. The recently developed array-
CGH technique combines the property of a complete genome scan of CGH along with 
the hybridization on sorted genomic DNA fragments from the microarray technology. In 
addition to that array CGH has been able to detect and quantify segmental aneuplody 
with a resolution comparable to that of FISH. Array-CGH, using DNA from uncultured 
cells, has been efficient in detection of low-level mosaicism, which could be missed by 
conventional cytogenetic analysis [Ballif   et al. 2006]. Large scale array CGH based 
studies using the Affymetrix 500K oligonuleotide array and the tiling path bacterial ar-
tificial chromosomes (BAC) array have identified copy number variations in 12% of the 
human genome [Zhang et al. 2007]. Froyen and collegues have developed a full cover-
age X chromosome tiling array CGH for the detection of copy number alterations in 
patients with suspected XLID [Froyen et al. 2007]. Complementary DNA microarray 
technology has been developed in recent years to perform large scale quantitative analy-
sis of gene expression at the transcript level. Zhang and collegues have recently ma-
naged to use a custom human X chromosome cDNA microarray to identify the candi-
date genes responsible for XLID [Zhang et al. 2007]. However this approach is limited 
by requiring expression of potential candidate genes in accessible tissues and also by its 
inability to identify candidate genes with mutations that do not alter transcript levels. 
Microarray technology was first used first time in a microarray – based copy number 
analysis of all human telomeres in patients with Intellectual Disability [Veltman et al. 
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2002]. The power of microarray technology is being fully utilized for unbiased whole- 
genome copy number analysis [Koolen et al. 2008]. 
 
2.7.4 Cytogenetic methods  
Karyotype analysis, biopsy of amniocytes or chorionic villi, is the most descriptive pre-
natal diagnostic tool to detect chromosome abnormalities. However, this method is time 
consuming. To reduce the level of distress among parents, efforts have been made to 
develop a very quick diagnostic test for specific chromosome abnormalities. Trisomies 
of chromosomes 13, 18 or 21 (Patau, Edwards or Down syndrome respectively) and sex 
chromosome aneuploidies (e.g. Turner syndrome) are the most characteristic chromo-
some abnormalities detected at amniocentesis [Ryan et al. 2005]. 
 
2.7.5 Next generation sequencing  
Recent advances in the next generation sequencing technologies have helped the re-
searchers to explore both rare and common disorders. While the whole genome se-
quencing still remains quite costly for most of the applications, exome sequencing is a 
technique which is the limelight and focuses on the protein coding portion of the ge-
nome only. There are currently three major exome enrichment platforms: Agilent Sure 
Select Human All Exon 50Mb, Roche/Nimblegen‘s SeqCap EZ Exome Library v2.0 
and Illumina‘s TreSeq Exome Enrichment. [Michael et al. 2011].  The exome consists 
of all the exons of a genome that are transcribed into a mature RNA. Protein coding 
genes constitute about 1% of the human genome but harbour 85% of the mutations with 
affect on disease related traits .[Bamshad et al. 2011]. Exome sequencing is used syn-
chronously with two sampling strategies: family –based phenotypes (to exploit parent 
child transmission patterns) and extreme phenotypes. In families where multiple indi-
viduals are affected with a common trait, one methodology will be to sequence the most 
distally related individuals.  
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Figure 9. To Illustrate the Workflow of Exome sequencing from genomic DNA extraction to biological 
interpretation and the identification of a casual mutation. The workflow is categorized into 3 main steps a) 
Sample Preparation and Sequencing, b) Primary Data Processing, c) Secondary Data Processing. Figure 
directly adapted from Chee- Seng Ku et al. 2012. 
 
Another alternative would be the family based approach which is useful in identifying 
de novo variants, it involves sequencing parent-offspring trios in which only the 
offspring is affected. Exome sequencing of a parent –child trios have been found to be 
an effective concept for identifying de novo coding mutations. This approach is appli-
cable to gene discovery in disorders where most of the cases are sporadic and also when 
a dominant mode of inheritance is speculated [Hoischen et al. 2010]. Most of the Men-
delian disorders are caused by the exonic mutations or splice site mutations that change  
the amino acids sequence of the affected gene. Exome sequencing is a very powerful 
tool for the discovery of Mendelian diseases in situations where the conventional ap-
proaches have failed [Biesecker et al. 2010]. Exome sequencing for the first time has 
been successful for the discovery of a novel mutation underlying an autosomal recessive 
non-syndromic mental retardation in the TECR gene on chromosome 19p13 [Caliskann 
et al. 2010]. A notable  accomplishment of the whole exome sequencing has been in 
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discovering that de novo single nucleotide variants contributes to the intellectual disabil-
ity [Vissers et al. 2010] and to children with sporadic autism [O‘Roak et al. 2011]. It has 
been affirmed that the power of whole exome sequencing plays a very substantial role  
in identifying the genetic basis of  various human diseases. In a recent study the largest 
published so far deep sequencing has revealed  disease causing variants in 50 novel 
genes for recessive cognitive disorders, it has also assisted  in revealing additional muta-
tions in 23 genes earlier implicated in intellectual disability or connected  neurological 
disorders. [Najmabadi  et al.  2011]. 
 
 
Figure10. Commonly adopted approaches to identify  causal mutations. The 3 main criterias which are 
used to filter the less likely causal variants are 1) removing common variants, 2) focusing on deleterious 
variants, and 3) predicting and retaining variants with functional  effects. Adapted from Chee- Seng Ku et 
al. 2012. 
 
By targeting the specific regions of interest selective DNA enrichment improves the 
overall cost and efficiency of the NGS [Rehman et al. 2010; Volpi et al. 2010]. Targeted 
sequencing focuses on all protein coding subsequences (the functional exome), which 
requires roughly 5% as much sequencing compared to that what is needed for the entire 
human genomes [Pussegoda 2010; Senapathy et al.  2010]. This present scheme helps in 
reducing the overall cost for the sequencing a single individual. Commercially available 
products for targeted sequence –enrichment includes Agilent‘s SureSelect and Nimble-
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gen‘s ASeqCap, Illumina‘s TruSeq. However the parallel short –read strategy of NGS 
opens to many hurdles for the bioinformatics to comprehend the short reads and the 
genetic alterations in human genomes [Myers et al. 2008]. The assets of the NGS can 
only be utilized when bioinformaticians are able to decipher and make use of the short 
read sequences, including alignment, assembly [ Salzberg et al. 2008]. NGS technolo-
gies will certainly allow us to identify all the causative variants including the ―rare va-
riants‖ within the individual. It is also strongly anticipated that the whole genome se-
quencing or the exome sequencing will make influential impact to our understanding of 
the genetic etiologies that contribute to the complicated human disease as well as the 
genetic basis of genomics. 
 
 
Figure 11. Integrated diagnostic/research information workflow. A patient presents with an idiopathic 
intellectual disability and her exome is sequenced in diagnostic laboratory. Variants are automatically 
annotated with respect to population frequency, evolutionary conservation, predicted effect on transcript 
expression or splicing, effect on protein function, and are checked against the databases of proven disease 
causing mutations. To make this process faster, all the variant data are also deposited into a local database 
of genetic variation. The laboratory then undertakes a targeted analysis of the set of genes known to be 
potentially causative of her condition, and information about the mutation in those genes are reported 
back again to the clinicians.  In cases where no causative mutation is found, her sequence data are stored 
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and periodically reanalyzed. Full analysis of a patient‘s exome along with the sequencing of parents or 
siblings‘ exomes may result in the identification of new potential candidate genes.  (Figure modified from 
Topper et al. 2011) 
2.8 Molecular Basis of Intellectual Disability 
The intricacy of the genes accountable for intellectual disability can be understood in 
terms of modules of several genes acting together in a single pathway or complex, re-
sulting in an equivalent phenotypes when mutated. Functional correlations have helped 
in identification of approximately 450 genes that have been found to be associated in ID 
[Inlow et al. 2004]. Several general molecular and cellular mechanisms underlying the 
pathophysiology of intellectual disability can be identified, including neurogenesis, neu-
ronal migration, synaptic functions, and transcription and translation [Chelly et al. 
2006]. Disturbed neurogenesis is commonly noticed in intellectual disability disorders 
comprising microcephaly, and these conditions seem to have a common origin in defec-
tive centrosome function and DNA repair response pathways [Kiaindl et al. 2010]. 
Larger groups of intellectual disorders refequently involve sharing biological functions 
in synapse formation and plasticity, cellular signaling, and transcriptional regulation. 
During the development and until adolescence, the brain is vulnerable to broad structur-
ing of neuronal connectivity by the formation and elimination of synapses. The dynamic 
regulation of synaptic connectivity is very critical for the various aspects of learning, 
memory, and cognitive functions in the adult brain. Synapses and spines are highly ac-
tive in their outlook and can undergo rapid structural changes in response to stimuli. 
This property is attributed to as the synaptic plasticity, and is believed to be involved in 
learning and memory [Lamprecht et al. 2004]. Functional analysis of the normal and the 
disrupted synaptic functions of intellectual disability associated proteins have aided us 
in learning about these processes. Several different mechanisms involving ID genes care 
responsible for the impaired synaptic plasticity and therefore they are known to affect 
cognitive function. Local regulation of protein levels in the PSD is a substantial me-
chanism in the control of synaptic plasticity. Another level of regulation of the PSD 
proteins is through the ubiquitin –mediated protein turnover. A large number of ID pro-
teins have been found to be precisely involved in UPS- mediated protein degradation, 
including UBE3A, UBE2A, HUWE1, CUL4B, and UBR1. Thus it reveals that tight 
regulation of postsynaptic protein levels is crucial for normal learning and memory 
processes. Dendritic spine morphology is highly plastic in nature and changes of shape 
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or size of spines can change within seconds. The dynamic morphology of spines is a 
result of continous polymerization and breakdown of actin filaments and dynamic mi-
crotubules in the spine [Jaworski et al. 2009]. 
 
 
Figure 12: Mechanism how intellectual disability proteins act on the synaptic membranes. The neuro-
transmitter content is relased after fusion into the synaptic cleft activating neurotransmitter receptors 
at the postsynaptic cell membrane and leading to the opening of ion channels followed by generation 
of a postsynaptic potential (Figure adapted from van Bokhoven at al. 2011.) 
 
There is increasing evidence that breakdown of signaling pathways both in excitatory 
glutamatergic neurons and in inhibitory GABAergic neurons contribute to the cognitive 
impairment and behavioral anaomalies in ID and ASD [Malinow  et al. 2002]   
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Figure13. Postsynaptic protein networks and pathways involving intellectual disability (ID) proteins. 
Figure modified from van Bokhoven et al. 2011.  
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3. AIMS OF THE PRESENT STUDY  
 
1. To identify a mutation in the Finnish family with intellectual disability of unknown 
cause. 
2. To investigate the functional effect of the mutation. 
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4. MATERIALS AND METHODS 
4.1 The family material 
The family pedigree is shown in Figure 14. The family belongs to the material consist-
ing of seven families with at least three affected males whose diagnosis has remained 
unknown since 1980s (data not shown). In 2004 a total of 88 multiallelic microsatellite 
markers on the X-chromosome were analyzed in these families. In one family a novel 
mutation in PAK3 was identified [Peippo M et al., 2007]. Using X-chromosomal CGH-
array a duplication in hydroxysteroid dehydrogenase HSD17B10 and the E3 ubiquitin 
ligase HUWE1 genes on Xp11.2 was identified in another family [Froyen G et al. 
2008]. Due to long common haplotypes that contained numerous genes in the remaining 
five families the identification of the causative gene was too expensive and time-
consuming and was not done. The Ethics Committee of the Helsinki university hospital 
approved the study. Informed written consent was obtained from all the participating 
individuals or their parents. 
 
 
Figure 14. The family pedigree under study. 
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4.2 DNA isolation 
10 ml whole blood was collected in the EDTA vials from the individuals participating in 
the study. Lymphocytes in the samples are lysed using Igepal CA-630 Sigma to release 
the nucleus from the cell and a DNA stabilizing agent was added to the sample. The 
samples were then centrifuged to pellet the nuclei after which the pellet was washed 
using TKM1 buffer. SDS-detergent was added to dissolve lipids and release the DNA 
from the nuclei into the solution. The remaining proteins are precipitated and removed 
using a high concentration salt solution after which the DNA is precipitated using abso-
lute ethanol. The DNA was finally dissolved and stored in TRIS-EDTA and the concen-
tration and the purity of the sample was measured using the NanoDrop. 
4.3 Exome Sequencing  
4.3.1 Exon enrichment and high throughput sequencing 
Exons from the homozygous intervals were enriched with custom-made Agilent Sure 
Select DNA capture arrays including an average of 60 bp of flanking sequence on either 
side of the exon and sequenced on an Illumina Genome Analyzer II yielding 76 bp sin-
gle reads. 
4.3.2 Sequence coverage of targeted exons 
More than 98% of the targeted exons were covered by at least four non redundant se-
quence reads, each with a PHRED like quality score of 20 or above. 
 
4.3.3 Calling of Single Nucleotides Polymorphisms  
To detect the single nucleotide polymorphisms high quality reads were aligned to the 
human reference genome by SOAP2.20 with default settings. 
4.3.4 Filtering out polymorphisms and selection of disease causing 
variants 
Also to eliminate previously reported, non pathogenic changes, all sequence variants 
were filtered against dbSNP. In addition to it the OMIM catalogue 
/http://www.ncbi.nlm.nih.gov/omim) and the Human Gene Mutation Database (HGMD, 
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http://www.hgmd.org/) were used as filter to identify all previously described pathogen-
ic changes.  
 
Figure 15. Variant calling, filtering and prioritization scheme adapted from Najambadi et al. 
2011. 
 
Several different measures were used to rank and screen the plausible disease causing 
missense changes or small in-frame deletions.  Other criterias included: 1) the presence 
of a single non-polymorphic variant in the family; 2) the evolutionary conservation of 
the relevant nucleotide, as defined by the PhyloP score; 3) the pathogenicity of these 
variants, as predicted by PolyPhen2, SIFT etc and  4)  the available biological and med-
ical evidence supporting a role of this gene in the brain function, including disease links 
in humans and animal models and a range of other functional clues. Variants were vali-
dated by Sanger Sequencing. [Najmabadi et al.  2011]. 
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4.4 PCR –Sequencing  
PCR for sequencing reactions was performed in a 15 µl reaction volume. The reaction 
volume contained 220pmol of both primers and 10nmol of each nucleotide. The poly-
merase enzyme used in this reaction was Dynazyme II (Finnzymes). 
The DNA of the study subjects were amplified by the polymerase chain reaction (PCR) 
using 2720 Thermal Cycler (Applied Biosystems). The polymerase chain reaction con-
dition were as follows: 1 min at 95 °C  followed by 35 cycles of the denaturation step of 
30 sec at 95 °C, annealing step of 20 sec at 55 °C, the elongation step of 1 min at 72 °C   
and the final extension for 10 min at 72 °C.  
PCR products were separated by electrophoresis on 1.5 % agarose gel with ethidum 
bromide to verify the success of the PCR reaction. A 100 bp size standard (O‘Range 
ruler 100bp DNA ladder, Fermentas) was included to detect the size of the PCR prod-
ucts. Purification of the PCR products was done using ExoSAP IT (Affymetrix). It con-
sisted of 15 min incubation at 37°C followed by enzyme activation at 80°C for a further 
15 min. The sequencing was performed in a volume of 10µl with BigDye 3.1 terminator 
(Applied Biosystems) according to manufacturer‘s instructions. The sequencing reac-
tion was performed in 25 cycles  for 1 min with  initial  denaturation at 96 °C, 10 s de-
naturation at 96 °C, 5s primer annealing at primer specific temperature (55 °C), 4 min 
extension at 60 °C. PCR and sequencing primers are presented. Sequenced products 
were electrophoresed on an ABI 3730 DNA Analyzer (Applied Biosystems) and base 
calling was performed using Seqencing Analysis 5.2 software (Applied Biosystems). 
Reference sequence was obtained from the UCSC Human Genome Browser and se-
quence analysis was performed using Sequencer 4.8 (Gene Codes, USA). 
 
4.5 Transcript Analysis 
Patients with mutations leading to abnormal mRNA splicing were further studied 
through transcript analysis. 
 
4.5.1 RNA Isolation 
Blood samples were collected in PAX-gene RNA-tubes (Qiagen).  RNA was isolated 
using the PAXgene Blood miRNA kit (Qiagen). The total RNA was purified from the 
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stabilized blood samples using the PAXgene silica membrane technology. PAXgene 
Blood RNA tubes were first centrifuged to pellet the samples, then washed with water 
and resuspended in Buffer BM1. Followed by the digestion in Buffer BM2 with protei-
nase K, the samples were homogenized by centrifugation through PAXgene shredder 
spin columns. Isopropanol was then added to the samples to optimize the binding condi-
tions and the samples were then centrifuged through PAXgene RNA spin column whe-
reby the total RNA binds to the PAXgene silica membrane. The bound RNA was sub-
jected to DNase digestion to remove genomic DNA contamination and washed with 
buffer BM3 followed by Buffer BM4. Pure RNA was then eluted in buffer BR5. 
 
4.5.2 RNA Integrity Check  
RNA integrity was checked with the help of the Agilent 2100 Bioanalyzer. The chip 
used to measure the samples was first primed using a gel-dye mix and the chip priming 
station. 5 µl of the RNA 6000 Nano marker was then loaded to the ladder well and each 
sample well in the chip, followed by the loading of 1 µl of the ladder and each sample 
into the chip. The chip was then briefly mixed for 1 minute and then loaded into the 
Bioanalyzer.  The run was started using the software connected to the computer. The 
software automatically allocates each sample a RIN, which usually ranges from 1 to 20. 
 
4.5.3 cDNA synthesis  
5 µg of the total RNA was reverse transcribed using the SuperScript III First Strand 
synthesis (Invitrogen) to generate the complementary cDNA synthesis. cDNA synthesis  
was performed in the first step using 5 µg  total RNA with 50 µM  oligo(dT) primers 
along with 10mM dNTP mix and DEPC treated water  in a 10 µl  reaction volume. The 
reaction mix was incubated at 65 °C for 5 minutes and then placed on ice for 1 minute. 
cDNA synthesis mix comprising of the following components 10X RT buffer, 25mM 
MgCl, 0.1M DTT, RNaseOUT and Superscript III RT was prepared and 10 µl of cDNA 
synthesis mix was added to each of the RNA/primer mixture and incubated for 50 mi-
nutes at 50 °C, reaction was terminated at  85 °C for 5 minutes. Finally 1 µl of RNase H 
was added and incubated for 20 minutes at 37°C. In the second step PCR was per-
formed in separate tubes using 10X High Fidelity buffer, 10 Mm dNTP, 50 Mm 
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MgSO4, forward and the reverse primers (20 µM gene specific primers), Platinum Taq 
DNA polymerase and autoclaved water to a  50 µl  reaction volume. PCR reaction was 
carried out using 2 µl of cDNA. All PCR reactions were performed with a 2720 Ther-
mal Cycler (Applied Biosystems). Initial denaturation at 94 °C for 1 minute followed by 
denaturation at 94 °C for 30 seconds, DNA amplification was carried out in a 35 cycles 
of 30 seconds annealing at temperature 55 °C, extension at 72 °C and the final extension 
at 72 °C for 7 minutes. 
 
4.5.4 Gel Purification  
Gel purification was done with the help of Pure Link Quick Gel Extraction kit. The de-
sired band was excised using a clean sharp razor blade. The gel slice containing the 
DNA fragment was weighed and then placed into 1.5 ml polypropylene microcentrifuge 
tube. Then 3 volumes of Gel solubilization Buffer were added to 1 volume of gel. The 
tube containing the gel slice and the gel solubilization buffer was placed into a 50
0
C 
water bath and incubated for 10 minutes. When the gel slice seemed to be dissolved, the 
tube was incubated for additional 5 minutes. The dissolved gel piece was then placed 
onto a Quick Gel Extraction Column containing silica membrane. The DNA was bound 
to the membrane either by centrifugation or vacuum extraction. The membrane was then 
washed with the 500 µl Wash buffer containing ethanol to remove the impurities and 
the purified DNA was then eluted into a recovery tube using 50 µl Elution Buffer 
(10Mm Tris-Hcl, pH 8.5). 
 
4.6  Bioinformatics Analysis 
Primers were designed by Primer3 and sequence comparison was done with the help of 
NCBI-BLAST. Clustal-W and LALIGN programs were used to compare the protein and 
the DNA sequences. The pathogenicity of the sequence variants was analyzed with the 
help of NNsplice (http://www.fruitfly.org/seq_tools/splice.html), PolyPhen2 (http:// 
genetics.bwh.harvard.edu/pph/).  
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5. RESULTS 
 
5.1 Clinical Results  
The index patient is a 30-year-old man with a severe learning disability. He was born 
from a pregnancy complicated by pre-eclampsia. A cesarean section was performed at 
term due to a prolonged delivery. His birth weight was 2920 grams and length 49 cen-
timeters. Apgar scores were 7, 8, and 9 after 1, 5, and 10 minutes. After birth dysmor-
phic features were noted consisting of abnormal auricles, an asymmetric thorax, and a 
small penis. At 10 months spasticity was observed in the hands. At 18 months hypoto-
nia and ataxia were detected, and also, epilepsy was diagnosed. He was able to walk 
independently at 2 years. Brain CT, ERG, and VEP were normal at 22 months. Karyo-
type and cytogenetic fragile-X analysis gave normal results. At a clinical geneticist´s 
consultation at 2 years a prominent forehead, up-slanting palpebral fissures, and hyper-
extensible fingers were seen. At 30 years he had no speech. He walks in a slightly for-
ward-flexed walking posture with small steps, and does not move hands. He is constant-
ly wandering around and has aggressive bursts. 
The older one of index patient´s maternal male cousins is a 45-year-old man with a 
moderate learning disability. This man was born after an uneventful pregnancy and de-
livery at term with a birth weight of 2650 grams, and a length of 46 centimeters. Apgar 
score was 10 at 1 minute. After birth he had feeding difficulties. The psychomotor de-
velopment was delayed from birth. He learned to walk at 26 months. At 6 years he used 
only two words. At that time tremor intentionalis was diagnosed. Strabismus was seen 
in the eye investigation at 9 years. Also, a generalized slowing and disorganization of 
the EEG was seen. No seizures have occurred. Bone age was delayed. Karyotype was 
normal. He was referred to the Department of Medical Genetics, The Family Welfare 
Federation, Helsinki, at 17 years. Dysmorphic features were noted consisting of a high 
forehead, deep set eyes, hyperplastic supra-orbital ridges, up-slanting of palpebral fis-
sures, abnormal and low-set ears, and a broad base to nose. He also had hypotonia and 
pes planus. At 45 years he uses two-word sentences, and walks. He has a pleasant per-
sonality 
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Table 4. The phenotypes observed in patients of the CUL4B family with XLID.  
Measure III-8       III-4          III-3  
Age 30                        45            39  
Birth Weight(gm) 2920                   2650           3080  
Height(cm) 49                        46           49  
ID(level) Severe                Moderate       Moderate  
Motor Delay Yes  Yes            Yes  
Speech Delay Yes                     Yes            Yes  
Tremor Yes                       Yes             Yes  
Seizures Yes                     No             No   
Gait Abnormality Yes                     No            No  
Malformed low set ears Yes                     Yes                             Yes  
Gynaecomastia Yes                     Yes            Yes  
Short feet No                      Yes            Yes  
Prominent lower lip No                       No            Yes  
Small Testes Yes                      Yes            Yes  
Kyphosis Yes                      No             No  
Behavioural problems Yes                      No             No   
Sandal Gap Yes                      Yes             Yes  
Narrow palpebral fissures No                       Yes             Yes  
Syndactyly  Yes                      Yes                         Yes  
 
The younger brother of index patient´s maternal cousins is a 39-year-old man with a 
moderate learning disability He was born after an uneventful pregnancy and delivery at 
37 weeks of gestation with a birth weight of 3080 grams and a length of 49 centimeters. 
Apgar score was 9 at 1 minute. He learned to walk at 13 months. At 2 years speech de-
lay was diagnosed. The audiological study was normal. Strabismus was seen in the eye 
examination. The EEG analysis revealed a generalized slowing and disorganization, but 
no signs of paroxysmal discharges were seen. Karyotype and cytogenetic fragile-X 
analysis gave normal results. He was referred to the Department of Medical Genetics, 
The Family Welfare Federation, Helsinki, at 12 years. Dysmorphic features were de-
tected consisting of a high forehead, down-slanting palpebral fissures, a broad base to 
 36 
nose, and abnormal and low-set ears. Also brachydactyly, II-III syndactyly, pes planus 
and hypotonia were detected. At 39 years he uses single words, and walks. He has an 
easy-going personality. 
 
5.2 Sequencing results and mutation analysis  
Exome sequencing performed in Max Planck institute, Berlin, revealed single base 
substitution T > C in intron 20 at position Chr X:-119,666,274 (GRCh 37/hg19) in in-
dex patient (III-8). Sequencing of genomic DNA of four affected male patients in Fin-
land showed that the mutation was found in three of the four affected patients. The 
mothers (II-4 and II-6) were carriers of the mutation. To analyze the frequency of the 
mutation in the Finnish population we screened 200 anonymous blood donors and did 
not find any mutation 
 
 
 
A) PATIENT II-6 
 
 
B) PATIENT III-7 
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                                                      C)  INDEX PATIENT III-8 
 
 
 
D) PATIENT II-4 
 
 
 
E) PATIENT III-4 
 
 
 
F) PATIENT III-3 
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G) PATIENT  III-7 
 
Further we performed Direct Sequencing of the RT-PCR products, which revealed the 
deletion of 78bp from exon 20 and 2bp deletion from exon 21, therefore leading to a 
total deletion of 80 bp nucleotides resulting into a premature stop codon at D806X. 
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STOCODON 
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We also did a pairwise alignment to strengthen our results. With the help of EMBOSS 
Needle alignment program, we aligned our patient‘s cDNA sequence with the RefSeQ 
sequence of the CUL4B gene. Patient III-7 ‗ s cDNA sequence aligned completely with 
the reference sequence  confirming that he did not have the CUL4B mutation and exon 
20 and exon 21 remain intact. Instead, in patients III-4, III-3 & III-8, a deletion of 78 bp 
of exon 20 and 2 bp of exon 21 were found to be deleted that resulted in premature stop 
codon 806 where aspartic acid in changed to a stop codon D806X the protein sequence. 
(p.806D>X) and thereby affecting the translation and the protein function. 
 
 
 
 
Figure 16. Lanes 1 & 7 represent the 200bp ladder. Lane 2 is Patient III-3, lane 3 is Patient III-4, 
Lane 4 is Patient III-8. Lane 5 is Patient who doesn‘t have the mutation and Lane 6 is the con-
trol sample. 
 
cDNA analysis in patients depicts a band with lower molecular weight than the control, 
demonstrating the deletion of a total of 80 bp nucleotides. 
 
  
 
 
 
 
 
 
M   M 
M 
1 2 3 4 5 6 7 
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Figure 17: To illustrate the CUL4B mutation  
 
 
 
 
 
 
 
Exon 1 Exon 2 Exon 20 Exon 21 Exon 22 
80 bp deletion  
STOP 
CODON 
(TGA) 
78 bp 
deletion 
2 bp 
deletion 
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6. DISCUSSION  
 
In this study we report a novel mutation in CUL4B gene in three out of four male pa-
tients with X-linked intellectual disability. The mutation follows the rule of X linked 
inheritance in the family. The mothers of the affected children are the mutation carriers. 
The mutation is rare since it has not been found in 200 anonymous blood donors.   
Previously mutations in CUL4B have been shown to cause Cabezas syndrome [Cabezas 
et al. 2000; Tarpey et al. 2007; Zou  et al. 2007]. Cabezas syndrome (MIM 300354) is a 
syndromic form of the X linked intellectual disability caused by mutations in the 
CUL4B gene. The main clinical features of the syndrome were first described in a single 
family [Cabezas at al., 2000]. The clinical features of Cabezas syndrome are severe 
mental retardation, speech impairment,  hyperactivity, seizures, intention tremor, in-
guinal hernia, small feet, syndactyly of the second and third toes and skin manifesta-
tions (hyperhydrosis and keratosis  pilaris) and craniofacial dysmorphic features [Cabe-
zas et al. 2009]. The clinical features in our patients were consistent with the Cabezas 
syndrome. A total of twelve families with CUL4B mutations have been reported till date 
[Badura-Stronka et al. 2010; Isidor et al. 2010; Tarpey et al. 2007; Zou et al. 2007; Ravn 
et al. 2011]. Wei et al. (1993)  initially reported a large X- linked pedigree in which five 
males were affected, Zou et al. 2007 had limited the candidate interval on Xq25 and  
identified a nonsense mutation in the CUL4B gene. 
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Table 5. Identified CUL4B variants.  
CUL4B VARIANT MUTATION 
CLASS 
NUMBER OF  
AFFECTED 
INDIVIDUALS 
PROTEIN 
CHANGE 
REFERENCE 
c.638C>T 
exon 4 
Missense 5 T213I Tarpey et al., 
2007 
c.901-2A>G 
exon 7 
Splice 3 not known Tarpey et al., 
2007 
c.1007_1011delTTAT 
exon 8 
Deletion  7 not known Tarpey et al ., 
2007  
c.1162C>T 
exon 9 
Nonsense 3 R388X Tarpey et al., 
2007 
c.1714C>T 
exon 14 
Missense 6 R572C Tarpey et al., 
2007 
c.2107A>T 
Exon 18 
Nonsense 3 K703X Badura  et al., 
2009 
c.2243T>C 
Exon 19 
Missense 4 V745A Tarpey et al., 
2007 
c.2493G>A 
Exon 20 
Splice 3 T831T Tarpey et al ., 
2007 
c. 2413T>C 
Exon 20 
Nonsense 3 D806X Our study* 
c.2566C>T 
Exon  21 
Nonsense 8 R856X Tarpey et al., 
2007   
 
 
Later on Cabezas reported an unrelated X linked family with six males with intellectual 
disability, small testes, muscle wasting in legs, abnormal gait, tremor and prominent 
lower lip [Cabezas et al. 2000]. In 2007 Tarpey identified mutations in the CUL4B gene 
in eight independent families. In parallel, a nonsense mutation in CUL4B was identified 
in the family [Zou et al. 2007] initially reported by Wei and coworkers. 
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Figure 18. Schematic representation of the genomic structure of mutations found in eight families along 
with the present mutation. Also schematic representation of the protein sequence. 
 
The CUL4B gene is composed of 22 exons and it encodes a protein of 913 amino acids 
(GenBank accession number NM_003588). CUL4B is a member of the family of cullin 
proteins that function primarily as scaffold proteins for a series of ubiquitin- protein 
ligase complexes that are responsible for regulating the degradation of cellular proteins 
[Hershko et al. 1992]. CUL4B has been found to be highly expressed in brain, testis, 
prostrate, colon and leukocytes. Cullins are a family of proteins that are characterized 
by the presence of distinct globular  C terminal domain (cullin-homology domain) and a  
series of N terminal repeats of a five- helix bundle .[Tarpey et al. 2007]. Cullin –RING 
complexes comprise the largest known class of ubiquitin ligases. Cullins are involved in 
several biological processes which include cell cycle regulation, signal transduction, 
oxygen regulation and DNA repair. The cullin family consists of at least seven members 
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in mammals. [Petroski et al. 2005]. Although CUL4A and CUL4B are 80 % identical in 
their protein sequences, CUL4B has a unique N terminus that is 149 amino acids longer 
than CUL4A. The N terminus of CUL4B assembles a specific ubiquitin ligase complex 
that targets the estrogen receptor alpha for degradation and this function has been found 
to play in role in this XLID. [Zou Y et al. 2009]. CUL4B is a component of the ubiquitin 
system. Ubiquitin-dependent proteolysis is an integral cellular mechanism for regulating 
protein activity. It is found to be implicated in diverse set of biochemical processes, 
including signal transduction, transcription receptor down-regulation, and endocytosis. 
It has also found to be involved in regulation of the cell cycle, immune response, devel-
opment, and programmed cell death. The proteolytic effects of ubiquitination have been 
widely studied, but it has been evident from the studies that it can influence activities of 
proteins through processes other than the degradation. [Petroski et al. 2005]. CUL4 is 
one of three founding cullins evolutionarily conserved from yeast to humans. Genetic 
analyses in various organisms have revealed a wide range of cellular and organismal 
functions mainly chromosome condensation, heterochromatin formation and DNA rep-
lication and repair [Harper et al.  2007]. CUL4 is present as a single gene in yeast, plants 
and invertebrates, but the vertebrates express two closely related paralogs CUL4A and 
CUL4B [Higa et al. 2006]. Deletion of CUL4B in mice has resulted in embryonic lethal-
ity  and defects in nervous system and heart development [Cox et al. 2010] whereas in 
humans loss of function mutations in CUL4B have been identified  in patients with X 
linked Intellectual Disability [Badura-Stronka et al. 2010; Isidor et al. 2010; Tarpey et 
al. 2007; Zou et al. 2007]. CUL4B mutations including missense, frame-shifts and pri-
mary truncations appear to be distributed throughout the gene and in most cases result in 
significant reduced levels of CUL4B protein expression [Kerzendorfer et al. 2010]. Tar-
pey et al.(2007) findings of eight families with XLID, approximately 3% of the 250 
families screened that have CUL4B mutations clearly indicates that this might be one of 
the most frequently mutated genes underlying XLID. 
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7. CONCLUSIONS 
 
 Although the traditional  gene mapping approaches  like karyotyping, homozygosity 
mapping , linkage analysis  have helped  in  understanding  Mendelian diseases  over 
the past few decades, they are still unable to detect all  forms of structural variation  
[Vissers et al. 2004; Lander et al. 1987; Kerem et al. 1989](Refer Table 6). Exome se-
quencing of a DNA sample from a single individual will generally reveal about 25,000 
variants; the challenge then lies not in finding variants, but in identifying the particular 
mutation accountable for disease.  In a single experiment it is possible that nearly all the 
coding content of the genome can be analyzed. 
It has been found that whole exome sequencing has the potential to identify the causa-
tive mutations in diseases with genetic and phenotypic heterogeneity [Ng et al. 2010; 
Gilissen et al. 2010]. Exome sequencing definitely has the potential to identify rare va-
riants. Apart for the success in finding mutations that causes rare, familial forms of dis-
ease it has been also successful in diseases caused by de novo mutations [Vissers et al. 
2010]. 
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Table 6: Mendelian Disease Gene Identification approaches 
Approach Applicable to Pros Cons 
 
Candidate gene Any disease Easy to perform for 
one or two genes; 
requires no mapping, 
can directly identify 
the causative va-
riant/mutation 
Relies heavily on current 
biological knowledge; suc-
cess rate very low 
Genetic mapping 
by karyotyping 
Any disease Easy to perform; no 
familial cases re-
quired; can detect 
(large) balanced events 
Low resolution, only detects 
large chromosomal aberra-
tions; mutation detection 
requires second step 
Genetic mapping 
by linkage analysis 
Inherited disease Easy to perform Requires large families, 
often identifies large loci; 
mutation detection requires 
second step 
Genetic mapping 
by homozygosity 
mapping 
Recessive monogenic 
diseases 
Small families can be 
used 
Most useful for consangui-
neous families; often identi-
fies large loci; mutation 
detection requires second 
step 
Genetic mapping 
by CNV analysis 
Monogenic/monolocus 
disease 
High resolution CNV 
screening; no familial 
cases required; can 
potentially identify 
small loci 
Only investigates CNVs; 
cannot detect balanced 
events, no base-pair resolu-
tion; mutation detection 
requires second step 
Whole exome 
sequencing (WES) 
Any disease Base-pair resolution 
exome-wide; detects 
most types of genomic 
variation; can directly 
identify the causative 
variant/mutation 
Unable to detect non-coding 
variants; limited resolution 
for CNVs and other structur-
al variation; coverage varia-
bility due to enrichment 
process; relatively expensive 
Whole genome 
sequencing (WGS) 
Any disease Base-pair resolution 
genome-wide; detects 
all types of genomic 
variation; can directly 
identify the causative 
variant/mutation 
Data analysis complex; even 
more expensive than exome 
sequencing 
Adapted from Christian Gilissen et al. 2011 
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Exome sequencing has already affirmed its worth in rapid genetic diagnosis and screen-
ing for many neurological diseases. (Singleton et al. 2011). However there are still vari-
ous restraints   to this technique, the exome data created by the current technologies are 
partial. It skips completely the structural variation. It has been also found that it also 
skips a certain set of exons and in case if the casual variants do not lie inside these ex-
ons, then they are not at all targeted. It is due to the partiality in the capture, sequencing 
and the various alignment processes. Whole genome sequencing is also being increa-
singly used. It has additional edge of capturing all of the exome and also it can afford to 
provide information on the structural variation present around the genome. Neverthe-
less, whole exome sequencing provides most of the advantages of the whole genome 
sequencing but with the lower costs in terms of sequencing as well as the storage and 
analysis of the data. [Majewski et al. 2011]. We anticipate that the whole exome se-
quencing in the coming years will drastically improve to elucidate the molecular basis 
of most remaining Mendelian disorders. 
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